In this episode, in honor of Breast Cancer Awareness Month, we speak with Ali Rogin, author of Beat Breast Cancer Like a Boss and award-winning producer of PBS NewsHour. Ali is what is commonly known as a breast cancer previvor, someone who knows they have a mutation that may lead to cancer and takes preventative steps to avoid a diagnosis. With the growth of genetic testing and precision medicine and the ability to isolate genes that can lead to cancer, more and more people may fall into the category of previvors. For instance, women that have the BRCA 1 or 2 mutation, as Rogin does, have a 70% chance of developing breast cancer by the age of 80. Rogin says progress in precision medicine has given these women options they would never have had before, enabling them to make proactive, informed decisions about their future health.

Precision Medicine Podcast

Author and Breast Cancer “Previvor” Ali Rogan on How Progress in Precision Medicine Empowers Patients to Make Informed Decisions

For our 50th episode, we welcome Dr. Kashyap Patel, medical oncologist and CEO of Carolina Blood and Cancer Center, current president of the Community Oncology Alliance (COA), and author of the book, Between Life and Death: From Despair to Hope. Dr. Patel explains the social determinants that can impact the quality of care and opportunity for precision medicine that patients—and specifically oncology patients—receive. For him, Covid-19 brought to light the impact that disparities in healthcare can have for all of us. He notes that one in three cancer deaths could be prevented if disparities didn't exist and that disparities result in 230B of excess expense. Read the full summary, listen and subscribe to the Precision Medicine Podcast here.

Dr. Kashyap Patel Tackles Oncology Treatment Disparities and Brings Light to the Darkest Areas of Cancer Care

In this episode of the Precision Medicine Podcast, Janine Morales, PhD, Chief Scientific Officer at Trapelo Health takes us inside the complex world of evidence-based decision making in oncology. Specifically, she dives deeps into some of the nuances in the latest targeted therapy approvals and explains how having access to a real-time knowledge-base and a team of experts that curate current clinical evidence can empower physicians to make more appropriate decisions at the point of care. Read the full summary here and subscribe to join us in the advancement of precision medicine.

Janine Morales, PhD On Applying Precision Medicine More Strategically With Molecular Testing

Dr. Howard McLeod is Medical Director for Precision Medicine at The Geriatric Oncology Consortium, a fellow of the American Society of Clinical Oncology and has worked on research projects with some of the most notable institutions around the world, including FDA, NIH, and NCI. We cover a lot of ground with Dr. McLeod in this podcast, including career advice, the advancement of precision medicine technology and the positive impact of COVID on telemedicine and clinical trials. Read the full summary and tune in to the audio here. 

Dr. Howard McLeod on Chasing the Fun and the Power of Collaboration in Precision Medicine

Bill Bonello, president of NeoGenomics Informatics, and Clynt Taylor, president of Trapelo Health, discuss challenges in precision medicine and how evidence-based technologies can help deliver more appropriate, value-based care to more patients.As a subtext to the discussion is the recent acquisition of Trapelo Health, creator of clinical decision-making platform Trapelo, by NeoGenomics Informatics, provider of bioinformatics services. This acquisition is aimed at improving access to precision medicine testing and treatment. Read the full summary and learn more about Trapelo here.

Bill Bonello and Clynt Taylor Examine the Future of Precision Medicine and How to Provide Better Access to More Patients

In this notable episode, Dr. Caroline Carney, Chief Medical Officer at Magellan Health, and Clynt Taylor, CEO at Trapelo Health, join us to discuss how collaborative technologies can help payers more effectively manage the cost of precision oncology while delivering the best outcomes for patients. Read the full summary.

Dr. Caroline Carney and Clynt Taylor Discuss Managing the Total Cost of Care in Precision Medicine

In this episode, Dr. F. Anthony Greco, medical oncologist at Tennessee Oncology, discusses the role that precision medicine has played in improving our diagnosis and treatment of cancer.

Dr. F. Anthony Greco Explains How Precision Medicine Has Led to Better Treatments for Cancers of Unknown Origins

In this Part 2 podcast featuring Dr. Gabriel A. Bien-Willner, Medical Director of the MolDX programat Palmetto GBA, we dive into the core challenges that payers face in navigating the explosion of precision medicine tests and treatments, and specifically how the prior authorization process can be streamlined by keeping payers updated on changes in coverage policy for new genes or CDx. Be sure to tune in to Part 1 with Dr. Bien-Willner who speaks about reshaping reimbursement policies for genetic and genomic testing.

Dr. Gabriel Bien-Willner Part 2: Helping Payers Adapt to the Paradigm Shift of Precision Medicine

Christopher Boone, Vice President and Global Head of Health Economics & Outcomes Research at AbbVie, shares his thoughts on how using data to understand a patient’s real-world environment can expand the practice of Precision Medicine.

AbbVie’s Christopher Boone Integrates Real-World Data with Precision Medicine for Better Patient Outcomes

It is fitting that our first guests on Season 3 of the Precision Medicine Podcast are Rob Metcalf, CEO of Concert Genetics and Clynt Taylor, CEO of Trapelo Health who are both innovators in precision medicine technology. What we learn from them in this episode is that after 20 years of hearing about the “promise of precision medicine,” technology has reached a critical point where it can begin to accelerate that progress. Read the full summary, listen and learn more here.

Precision Medicine is Coming Faster Than You Think: Guests Rob Metcalf and Clynt Taylor

In this episode, and in honor of lung cancer awareness month we had the opportunity to speak with Dr. Luis Raez, Medical Director and Chief of Hematology Oncology at Memorial Cancer Institute who focuses on treating lung cancer. Hear how the emergence of next-generation sequencing has changed his approach to lung cancer treatment, what notable discoveries in lung cancer have occurred over the last year, and how he sees COVID-19 impacting the treatment of cancer. Tune in to the full episode here.

Dr. Luis Raez Discusses the Impact of Precision Medicine in Lung Cancer Treatment

In the first of a two-part podcast, Gabriel A. Bien-Willner MD, PhD, FCAP, Medical Director at MolDX, and Chief Medical Officer at Palmetto GBA shares how he has helped implement payer controls and coverage and set policies for affiliated Medicare Administrative Contractors in 28 states. In the past, payers have had to navigate the growing field of precision medicine without the benefit of expertise, so their only guidance came from the NCCN or consultations with other experts in the field. Today, under his direction, Palmetto GBA is able to base its policies on evidentiary reviews, and he believes this form of evidence-based decision-making should be an industrywide standard.

Dr. Gabriel Bien-Willner Part 1: Reshaping Reimbursement Policies for Genetic and Genomic Testing

Dr. Mark Moasser, a physician-scientist and breast cancer specialist at the University of California, San Francisco discusses his research focus on the HER2 oncogene, the latest trial findings and the importance of improving patient access to clinical trials. At Trapelo, connecting oncologists with patient-appropriate clinical trials is a major part of our mission, so we were grateful for the opportunity to talk to Dr. Moasser and learn more about his thoughts on this matter. Tune in to the full episode to learn more about his current research and perspective on the future of precision medicine.

Breast Cancer Specialist Dr. Mark Moasser Discusses Overcoming Barriers to Clinical Trial Access

In this episode, Clynt Taylor, CEO at Trapelo Health, talks with Lori Brisbin, Vice President of Precision Medicine at Texas Oncology, one of the largest practices in the United States. The discussion centers on how this expansive network of oncologists is leveraging the web-based Trapelo™ platform to provide evidence-based decision support to its physicians and bring precision medicine to the forefront of patient care

Lori Brisbin Explains How Trapelo Helps Keep Texas Oncology Ahead of the Precision Medicine Curve

Welcome to the Precision Medicine Podcast, where experts come to discuss the problems oncologists, reference labs, and payers face as precision medicine grows, and consider solutions for advancing the quality of patient-centered cancer care.

hubhopper

Precision Medicine Podcast

hubhopper